Related Experiment Video

Updated: Jun 8, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells

Buket Kosova1, Burcin Tezcanli, Huseyin Atakan Ekiz

  • 1Department of Medical Biology, Medical School, Ege University, Izmir, Turkey.

Leukemia & Lymphoma
|September 21, 2010
PubMed

Insights

STAT5A siRNA knockdown resensitized imatinib-resistant leukemia cells to chemotherapy by increasing apoptosis. This finding offers new strategies to overcome drug resistance in leukemia treatment.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • Signal transducer and activator of transcription (STAT) proteins are key regulators of cellular processes.
  • STAT proteins influence cell growth, differentiation, and survival.
  • Chemotherapeutic resistance, particularly to imatinib in leukemia, remains a significant clinical challenge.

Purpose of the Study:

  • To investigate STAT gene expression in imatinib-sensitive and -resistant K562 leukemia cells.
  • To determine the impact of STAT5A siRNA knockdown on imatinib sensitivity, cell proliferation, and apoptosis in K562 cells.

Main Methods:

  • K562 cell lines (imatinib-sensitive and -resistant) were utilized.
  • STAT5A gene knockdown was achieved using siRNA.
  • Cell proliferation was assessed using the XTT assay.
  • Caspase-3 enzyme activity was measured to evaluate apoptosis.

Main Results:

  • STAT5A siRNA transfection sensitized both imatinib-sensitive and -resistant K562 cells to imatinib.
  • Cell proliferation was reduced in cells treated with STAT5A siRNA and imatinib.
  • Significant increase in Caspase-3 enzyme activity was observed in both cell types post-treatment.

Conclusions:

  • STAT5A plays a crucial role in imatinib resistance in K562 leukemia cells.
  • STAT5A siRNA knockdown can overcome imatinib resistance by enhancing apoptosis.
  • Targeting STAT5A presents a potential therapeutic strategy to improve leukemia treatment outcomes.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...